Inscripta raises $30 million in capital
BOULDER — Inscripta Inc., a gene-editing technology company, has raised $30 million in capital.
The funding, filed with the U.S. Securities and Exchange Commission in a Form D dated Jan. 17, comes from the company’s existing investors.
In 2018, the Boulder-based company raised $85.5 million, according to a news release. The company raised more than $55 million in February 2018. The funding is an expansion of a Series C round. Investors include Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital and NanoDimension.
SPONSORED CONTENT
Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply
Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).
In September, Inscripta acquired Solana Biosciences.
BOULDER — Inscripta Inc., a gene-editing technology company, has raised $30 million in capital.
The funding, filed with the U.S. Securities and Exchange Commission in a Form D dated Jan. 17, comes from the company’s existing investors.
In 2018, the Boulder-based company raised $85.5 million, according to a news release. The company raised more than $55 million in February 2018. The funding is an expansion of a Series C round. Investors include Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital and NanoDimension.
In September, Inscripta acquired Solana Biosciences
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
